Raymond B. Mailhot Vega

Raymond B. Mailhot Vega

Auto-generated profile, based on publicly available information

Raymond B. Mailhot Vega

University of Florida, Jacksonville, FL

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
KPKo Un Park
Ko Un Park
MSMark R. Somerfield
Mark R. Somerfield
NANirupama Anne
Nirupama Anne
MBMuriel Brackstone
Muriel Brackstone
ACAlison K. Conlin
Alison K. Conlin
MTMylin A. Torres
Mylin A. Torres
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more. PURPOSE: To update the ASCO evidence-based recommendations on the use of sentinel lymph node biopsy (SLNB) in patients with early-stage breast cancer treated with initial surgery. METHODS: ASCO convened an Expert Panel to develop updated recommendations based on a systematic literature review (January 2016-May 2024). RESULTS: Eleven randomized clinical trials (14 publications), eight meta-analyses and/or systematic reviews, and one prospective cohort study met the inclusion criteria for this systematic review. Expert Panel members used available evidence and informal consensus to develop practice recommendations. RECOMMENDATIONS: Clinicians should not recommend routine SLNB in select patients who are postmenopausal and ≥50 years of age and with negative findings on preoperative axillary ultrasound for grade 1-2, small (≤2 cm), hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer and who undergo breast-conserving therapy. Clinicians may offer postmastectomy radiation (RT) with regional nodal irradiation (RNI) and omit axillary lymph node dissection (ALND) in patients with clinically node-negative invasive breast cancer ≤5 cm who receive mastectomy and have one to two positive sentinel nodes. Clinicians may offer SLNB in patients who have cT3-T4c or multicentric tumors (clinically node-negative) or ductal carcinoma in situ treated with mastectomy, and in patients who are obese, male, or pregnant, or who have had prior breast or axillary surgery. Clinicians should not recommend ALND for patients with early-stage breast cancer who do not have nodal metastases, and clinicians should not recommend ALND for patients with early-stage breast cancer who have one or two sentinel lymph node metastases and will receive breast-conserving surgery and whole-breast RT with or without RNI. Additional information is available at www.asco.org/breast-cancer-guidelines . This guideline has been endorsed by the American Society for Radiation Oncology (ASTRO).

18 March 2013 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
Henry S. ParkHenry S. Park
Henry S. Park
JSJ. D. Schoenfeld
J. D. Schoenfeld
RMR. B. Mailhot
R. B. Mailhot
MSM. Shive
M. Shive
RHR. I. Hartman
R. I. Hartman
LML. A. Mucci
L. A. Mucci
In this meta-analysis, we evaluated associations between statins and recurrence-free survival (RFS) following treatment of localized prostate cancer, with attention to potential benefits among patients treated primarily with radiotherapy (RT) versus radical prostatectomy. We identified original studies examining the effect of statins on men who received definitive treatment of localized prostate cancer using a systematic search of the PubMed and EMBASE databases through August 2012. Our search yielded 17 eligible studies from 794 references; 13 studies with hazard ratios (HRs) for RFS were included in the formal meta-analysis. Overall, statins did not affect RFS (HR 0.90, 95% CI 0.74–1.08). However, in RT patients (six studies), statins were associated with a statistically significant improvement in RFS (HR 0.68; 95% CI 0.49–0.93); this benefit was not observed in radical prostatectomy patients (seven studies). Sensitivity analyses suggested that primary treatment modality may impact the effect of statins on prostate cancer recurrence. Our meta-analysis suggests a potentially beneficial effect of statins on prostate cancer patients treated with RT but not among radical prostatectomy patients. Although limited by the lack of randomized data, these results suggest that primary treatment modality should be considered in future studies examining associations between statins and oncologic outcomes.

16 September 2013 in Cancer
Verified
Journal Article
Closed access
PDF file
RVRaymond B Mailhot Vega
Raymond B Mailhot Vega
JKJane Kim
Jane Kim
MBMarc Bussière
Marc Bussière
JHJona Hattangadi
Jona Hattangadi
AHAbby Hollander
Abby Hollander
SMShannon M MacDonald
Shannon M MacDonald

1 March 2019 in Practical Radiation Oncology
Verified
Journal Article
Open access
JWJean L. Wright
Jean L. Wright
SYSaeHee K. Yom
SaeHee K. Yom
MAMusaddiq J. Awan
Musaddiq J. Awan
SDSamantha Dawes
Samantha Dawes
BFBenjamin Fischer-Valuck
Benjamin Fischer-Valuck
GRGeorge Rodrigues
George Rodrigues
The comprehensive identification and delineation of organs at risk (OARs) are vital to the quality of radiation therapy treatment planning and the safety of treatment delivery. This guidance aims to improve the consistency of ontouring OARs in external beam radiation therapy treatment planning by providing a single standardized resource for information regarding specific OARs to be contoured for each disease site. The guidance is organized in table format as a quality assurance tool for practices and a training resource for residents and other radiation oncology students (see supplementary materials). The Task Force formulated recommendations based on clinical practice and consensus. The draft manuscript was peer reviewed by 16 reviewers, the American Society for Radiation Oncology (ASTRO) legal counsel, and ASTRO's Multidisciplinary Quality Assurance Subcommittee and revised accordingly. The recommendations were posted on the ASTRO website for public comment in June 2018 for a 6-week period. The final document was approved by the ASTRO Board of Directors in August 2018. Standardization improves patient safety, efficiency, and accuracy in radiation oncology treatment. This consensus guidance represents an ASTRO quality initiative to provide recommendations for the standardization of normal tissue contouring that is performed during external beam treatment planning for each anatomic treatment site. Table 1 defines 2 sets of structures for anatomic sites: Those that are recommended in all adult definitive cases and may assist with organ selection for palliative cases, and those that should be considered on a case-by-case basis depending on the specific clinical scenario. Table 2 outlines some of the resources available to define the parameters of general OAR tissue delineation. Using this paper in conjunction with resources that define tissue parameters and published dose constraints will enable practices to develop a consistent approach to normal tissue evaluation and dose documentation.

19 March 2016 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
PDF file
RVRaymond B. Mailhot Vega
Raymond B. Mailhot Vega
OIOmar Ishaq
Omar Ishaq
ARAnn Raldow
Ann Raldow
CPCarmen A. Perez
Carmen A. Perez
RJRachel Jimenez
Rachel Jimenez
SMShannon M. MacDonald
Shannon M. MacDonald

29 January 2015 in Cancer
Verified
Journal Article
Open access
PDF file
RVRaymond Mailhot Vega
Raymond Mailhot Vega
JKJane Kim
Jane Kim
AHAbby Hollander
Abby Hollander
JHJona Hattangadi‐Gluth
Jona Hattangadi‐Gluth
JMJeff Michalski
Jeff Michalski
SMShannon M. MacDonald
Shannon M. MacDonald
BACKGROUND: Proton therapy in pediatrics may improve the risk/benefit profile of radiotherapy at a greater upfront financial cost, but it may prove to be cost effective if chronic medical complications can be avoided. Tools to assist with decision making are needed to aid in selecting pediatric patients for protons, and cost‐effectiveness models can provide an objective method for this.METHODS: A Markov cohort‐simulation model was developed to assess the expected costs and effectiveness for specific radiation doses to the hypothalamus with protons versus photons in pediatric patients. Costing data included cost of investment and the diagnosis and management of growth hormone deficiency. Longitudinal outcomes data were used to inform risk parameters for the model. With costs in 2012 US dollars and effectiveness measured in quality‐adjusted life years, incremental cost‐effectiveness ratios were used to measure outcomes.RESULTS: Proton therapy was cost effective for some scenarios based on the difference in hypothalamic sparing. Although some scenarios were not cost effective, others were not only cost effective for proton therapy but also demonstrated that protons were cost saving compared with photons.CONCLUSIONS: The current results provide the first evidence‐based guide for identifying children with brain tumors who may benefit the most from proton therapy with respect to endocrine dysfunction. Proton therapy may be more cost effective for scenarios in which radiation dose to the hypothalamus can be spared, but protons may not be cost effective when tumors are involving or directly adjacent to the hypothalamus if there is a high dose to this structure. Cancer 2015;121:1694–1702. © 2015 American Cancer Society.